
At-Home Testing: COVID-19 Trends and Future Potential
Description
At-Home Testing: COVID-19 Trends and Future Potential
This first edition report At-Home Testing: COVID-19 Trends and Future Potential provides an overview of trends and developments in the home testing industry for the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This report covers trends that have occurred since the pandemic was declared in 2020 to the recent present – March 31, 2021.
For the purpose of this report, Kalorama Information concludes that the accepted definition of a home or self-test is one whereby the individual takes the sample, performs the test and then interprets the test result either alone or with the aid of an online consultation service. As of the time of publication in Spring 2021, the major market for COVID-19 self-tests is the United States, therefore the discussion presented in the report focuses on that geography.
Many non-instrumented point-of-care (POC) COVID-19 tests use immunoassays and molecular technologies. They have not been officially designated as home tests but do have the potential to migrate to home-based tests as is deemed necessary by public health agencies. These COVID-19 point-of-care molecular tests are therefore included in this Kalorama Information report.
The report discusses COVID-19 tests and technologies that are currently available and those that are expected to take their place. The report covers trends and issues concerning:
This first edition report At-Home Testing: COVID-19 Trends and Future Potential provides an overview of trends and developments in the home testing industry for the pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This report covers trends that have occurred since the pandemic was declared in 2020 to the recent present – March 31, 2021.
For the purpose of this report, Kalorama Information concludes that the accepted definition of a home or self-test is one whereby the individual takes the sample, performs the test and then interprets the test result either alone or with the aid of an online consultation service. As of the time of publication in Spring 2021, the major market for COVID-19 self-tests is the United States, therefore the discussion presented in the report focuses on that geography.
Many non-instrumented point-of-care (POC) COVID-19 tests use immunoassays and molecular technologies. They have not been officially designated as home tests but do have the potential to migrate to home-based tests as is deemed necessary by public health agencies. These COVID-19 point-of-care molecular tests are therefore included in this Kalorama Information report.
The report discusses COVID-19 tests and technologies that are currently available and those that are expected to take their place. The report covers trends and issues concerning:
- government support for COVID-19 home tests
- COVID-19 home test sample types
- COVID-19 home test modalities
- OTC and DTC trends in COVID-19 testing
- Abbott Laboratories
- Becton Dickinson & Company (BD)
- bioMérieux / BioFire Diagnostics
- Cepheid, A Danaher Company
- Fluidigm Corporation
- GenMark Diagnostics, Inc., A Roche Diagnostics Company
- LetsGetChecked/PrivaPath Diagnostics Limited
- Lucira Health
- LumiraDx
- Mesa Biotech
- OraSure Technologies, Inc.
- QIAGEN N.V.
- Quidel Corporation
- Roche Diagnostics
- Sherlock Biosciences
- Siemens Healthineers
Table of Contents
134 Pages
- Background
- Scope and Methodology
- Definitions
- Point of View
- Background
- U.S. EUA Tests and Home Test Services
- Canada's COVID-19 Test Initiative
- COVID-19 Test Initiatives in Europe and the UK
- Background
- Sample Self Collection Kits
- Nasal Swabs Maintain Market Dominance
- Saliva Sampling Gains Popularity
- Alternative Sampling Innovations
- Background
- Traditional Molecular - PCR, LAMP
- CRISPR & Biosensors
- COVID-19 Antigen Testing By Immunoassay
- COVID-19 Antibody Tests by Immunoassay
- Background
- OTC and DTC Initiatives
- And Now For Something a Little Bit Different
- Background
- What Is The Status Quo
- The Future for Home Covid-19 Tests
- Background
- Abbott Laboratories
- Becton Dickinson & Company (BD)
- bioMérieux / BioFire Diagnostics
- Cepheid, a Danaher Company
- Fluidigm Corporation
- GenMark Diagnostics, Inc.
- LetsGetChecked/PrivaPath Diagnostics Limited
- Lucira Health
- LumiraDx
- Mesa Biotech
- OraSure Technologies, Inc.
- QIAGEN N.V.
- Quidel Corporation
- Roche Diagnostics
- Sherlock Biosciences
- Siemens Healthineers
- What Test Categories May Benefit From At-Home Testing Trend?
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.